Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.
Radiopharm Theranostics Limited has announced a new application for the quotation of securities on the Australian Securities Exchange (ASX). The company plans to issue 12,599,991 options expiring on October 31, 2027, at an exercise price of $0.039. This move is part of a securities purchase plan, which could potentially strengthen the company’s financial position and support its ongoing projects in the radiopharmaceutical sector.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the healthcare industry, focusing on the development and commercialization of radiopharmaceutical products for diagnostic and therapeutic purposes. The company is engaged in creating innovative solutions for cancer treatment and diagnosis, aiming to enhance patient outcomes and expand its market presence.
Average Trading Volume: 5,896,644
Technical Sentiment Signal: Sell
Current Market Cap: A$61.17M
For detailed information about RAD stock, go to TipRanks’ Stock Analysis page.